Aaron Goodman: Let’s stop giving many cured young patients neuropathy

Aaron Goodman shared a post by Laura Korin, hematologist from Instituto Alexander Fleming in Argentina, on X/Twitter:

“There was never a role for brentuximab maintenance post auto for Hodgkin lymphoma my opinion. Let’s stop giving many cured young patients neuropathy.”

Quoting Laura Korin’s post:

“Is it time to challenge post ASCT maintence in HL as more effective salvage tx comes into light? Decreased duration of tx, decreased toxicity and decreased financial burden.”

For more information click here.
Source: Aaron Goodman/X and Laura Kim/X.

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.